Anillin actin binding protein (ANLN) is a biomarker of cancer progression and is overexpressed in lung adenocarcinoma. The aim of the present study was to investigate the role of ANLN protein and RNA in the development of lung adenocarcinoma. The ANLN protein sequence was downloaded from The National Centre for Biotechnology information, RNA sequencing (RNA-seq) data was obtained from The Cancer Genome Atlas database. All immunohistochemical staining pictures were adapted from the Human Protein Atlas. PyMOL software was employed to predict protein functional changes in response to mutations. Gene Set Enrichments Analysis was employed for pathway analysis. The results indicated that ANLN experiences genetic change and overexpression at the RNA and protein levels in patients with lung adenocarcinoma. Kaplan-Meier survival curve analysis revealed significant differences between high and low RNA-seq expression levels in ANLN, and patients exhibiting higher expression of ANLN had a relatively poor prognosis. Pathway analysis demonstrated that ANLN was involved in developmental processes via the regulation of nuclear division' pathway. In conclusion, ANLN has potential for use as a diagnostic and prognostic biomarker to diagnoseand predict the outcome of lung adenocarcinoma.
Keywords: anillin actin binding protein; bioinformatics; biomarker; lung adenocarcinoma.